CD19 and hematologic disorder: To date, the most prominent success in NK cell adoptive transfer has been with IL-15-enhanced CAR-NK products against CD19-expressing lymphomas, while progress in other hematologic malignancies and solid tumor targets remain in earlier investigational stages [6,181,185].